Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation.

A technology of DSM26943, HTF-F, applied in the fields of probiotics and their extracts, immunology and gastroenterology, anti-inflammatory compositions, and therapeutic uses for the treatment of inflammatory disorders

Inactive Publication Date: 2016-01-06
UNIVERSITY OF GRONINGEN +3
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no therapeutic application of strain HTF-F has been reported or suggest

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation.
  • Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation.
  • Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation.

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] Example 1: Phenotypic characterization of F. prausnitzii strain HTF-F and purification of the extracellular polymeric matrix

[0075] Although both F. prausnitzii strains HTF-F and A2-165 formed colonies with a slime-like appearance on solid agar, only strain HTF-F formed a slime-like biofilm in liquid culture ( figure 1 a). This phenotype is often associated with the production of extracellular polysaccharides and intercellular aggregated proteins (Flemming and Wingender 2010). The EPM of strain HTF-F was revealed by Gram staining ( figure 1 b), and observed in the transmission electron microscope as a diffuse and irregular surface layer ( figure 2 a, arrow), similar to the capsular polysaccharide (CPS) of Streptococcus suis ( figure 2 b, (Meijerink, Ferrando et al. 2012)). Cell-bound EPM produced by strain HTF-F was isolated, concentrated and filtered to remove possible bacterial contamination. EPM yield is about 2.5x10 11 bacteria produced 1.2 mg / ml of EPM. ...

Embodiment 2

[0076] Example 2: EPM of F. prausnitzii HTF-F reduces transcription and production of proinflammatory IL-12p70 in L. plantarum activated hDCs

[0077] The immunomodulatory properties of F. prausnitzii A2-165, HTF-F and EPM were tested in vitro using human monocyte-derived DC (hDC). DCs were chosen because they are one of the most important antigen-presenting cells with the ability to stimulate naive T cells located at mucosal sites and drive immune responses.

[0078] with L. plantarum ( Figure 4 a) Incubation of hDCs with F. prausnitzii strains A2-165 and HTF-F induced a large amount of IL-10 and a small amount of IL-12p70 compared to other lactic acid bacteria (not shown). The amount of IL-10 produced by hDC after incubation with strain HTF-F was lower than the amount of IL-10 produced after incubation with strain A2-165 ( Figure 4 a). However, the difference is not significant. Furthermore, the protective effect in vivo is more complex and may depend on additional fac...

Embodiment 3

[0081] Example 3: EPM of F. prausnitzii and strain HTF-F alleviates clinical symptoms of DSS-colitis

[0082] The potential protective effects of F. prausnitzii strains A2-165, HTF-F and EPM were evaluated in mice using a DSS-induced colitis model. Bacteria or EPM were administered intrarectally to mice, followed by DSS exposure ten days later and continued daily over a period of 8 days, with DSS administered in drinking water to induce colitis. The severity of colitis in individual mice in each group was evaluated by measuring disease activity index (DAI), histological lesion score of the colon, body weight and colon length. DAI and histological colonic lesion scores after DSS treatment were determined according to the scale (0-4) of Cooper et al. (Cooper, Murthy et al. 1993).

[0083] Although the score was higher than that of untreated mice ( Image 6 a) However, administration of F. prausnitzii A2-165, HTF-F and EPM significantly reduced DAI compared to colitis control m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to medicine, particularly immunology and gastroenterology. Specifically, it relates to probiotic bacteria and extracts thereof for therapeutic use for the treatment of inflammatory disorders such as inflammatory bowel disease. Provided is a composition comprising as active ingredient Faecalibacterium prausnitzii strain HTF-F (DSM 26943) or an extract thereof comprising extracellular polymeric matrix (EPM), and an acceptable carrier, diluent or excipient. Also provided is an anti-inflammatory composition comprising EPM extracted from F. prausnitzii strain HTF-F, and a method for preparing the same.

Description

technical field [0001] The present invention relates to a kind of medicine, especially relates to immunology and gastroenterology. In particular, the present invention relates to the therapeutic use of probiotics and their extracts for the treatment of inflammatory disorders such as inflammatory bowel disease and diseases associated with microbiota imbalance. The present invention also provides anti-inflammatory (probiotic) compositions, such as functional food, nutritional or pharmaceutical compositions, and methods of producing them, as well as ways to promote the survival of probiotics in the intestinal tract. Background technique [0002] Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, bloody stools, abdominal pain and weight loss. IBD is a chronic relapsing inflammatory disorder of unknown cause. IBD comprises two main conditions: ulcerative colitis (UC) and Crohn's disease (CD). UC primaril...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/741A23L1/30A61P29/00A61P1/00
CPCA61K35/74A23V2002/00A23K10/16A23K10/18A23K50/40A23L29/065A23L33/135A23L33/15A23L33/175A23L33/21A61K35/741A61P1/00A61P29/00A61P43/00A23V2200/32A23V2250/0616A23V2250/206A23V2250/5062A23V2250/5072A23V2250/7044A61K45/06
Inventor 赫曼努斯·约瑟夫·马丁努斯·哈尔姆森穆罕默德·谭威尔·可汗杰里米·威尔斯奥利安娜·罗西哈里·詹姆斯·弗林特西尔维亚·海伦·邓肯
Owner UNIVERSITY OF GRONINGEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products